Maravai Lifesciences Holdings Inc (MRVI)

Currency in USD
2.07
+0.05(+2.22%)
Real-time Data·
MRVI Scorecard
Full Analysis
10 analysts have revised their earnings downwards for the upcoming period
MRVI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.032.11
52 wk Range
1.679.95
Key Statistics
Prev. Close
2.03
Open
2.05
Day's Range
2.03-2.11
52 wk Range
1.67-9.95
Volume
480.78K
Average Volume (3m)
1.82M
1-Year Change
-77.69%
Book Value / Share
2.09
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MRVI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.06
Upside
+144.57%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Sell

Maravai Lifesciences Holdings Inc Company Profile

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Maravai Lifesciences Holdings Inc SWOT Analysis


mRNA Manufacturing
Maravai's Flanders 2 GMP mRNA site attracts customers, positioning the company for growth in the expanding mRNA therapeutics and vaccine market
Financial Outlook
Analysts project mixed performance with revenue of $276.9M TTM. Price targets range from $10 to $15, reflecting varied views on growth potential
Segment Performance
Explore the contrasting fortunes of Maravai's business segments: NAP's robust 10% growth versus BST's 5% decline, impacting overall company strategy
Strategic Investments
Delve into Maravai's R&D collaborations and facility expansions, balancing short-term margin pressures against long-term growth in cell and gene therapy
Read full SWOT analysis

Maravai Lifesciences Holdings Inc Earnings Call Summary for Q1/2025

  • Revenue beat expectations at $47M, but EPS missed at -$0.08; stock rose 7.07% after hours to $2.14
  • GAAP net loss widened to $53M from $23M in Q1 2024; adjusted EBITDA fell to -$11M from +$8M last year
  • Company maintains $185-$255M full-year revenue guidance; Q2 forecast of $45-50M revenue
  • Strategic focus on innovation and cost reduction in mRNA; launched new Poly A plus line and CRISPR guides
  • Strong $285M cash position; addressing profitability concerns amid post-pandemic market competition
Last Updated: 12/05/2025, 23:16
Read Full Transcript

Compare MRVI to Peers and Sector

Metrics to compare
MRVI
Peers
Sector
Relationship
P/E Ratio
−1.8x−2.9x−0.5x
PEG Ratio
0.11−0.010.00
Price/Book
1.8x1.2x2.6x
Price / LTM Sales
2.2x2.6x3.3x
Upside (Analyst Target)
146.3%37.8%43.4%
Fair Value Upside
Unlock21.2%7.1%Unlock

Analyst Ratings

6 Buy
6 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.06
(+144.57% Upside)

Earnings

Latest Release
May 12, 2025
EPS / Forecast
-0.08 / -0.07
Revenue / Forecast
46.90M / 45.60M
EPS Revisions
Last 90 days

MRVI Income Statement

People Also Watch

18.35
SRPT
+2.17%
15.34
IMVT
-2.48%
18.02
URGN
-3.07%
7.54
ASPN
-0.40%
5.16
REPL
-5.93%

FAQ

What Stock Exchange Does Maravai Lifesciences Trade On?

Maravai Lifesciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Maravai Lifesciences?

The stock symbol for Maravai Lifesciences is "MRVI."

What Is the Maravai Lifesciences Market Cap?

As of today, Maravai Lifesciences market cap is 515.69M.

What Is Maravai Lifesciences's Earnings Per Share (TTM)?

The Maravai Lifesciences EPS (TTM) is -1.16.

When Is the Next Maravai Lifesciences Earnings Date?

Maravai Lifesciences will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is MRVI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Maravai Lifesciences Stock Split?

Maravai Lifesciences has split 0 times.

How Many Employees Does Maravai Lifesciences Have?

Maravai Lifesciences has 580 employees.

What is the current trading status of Maravai Lifesciences (MRVI)?

As of 08 Aug 2025, Maravai Lifesciences (MRVI) is trading at a price of 2.07, with a previous close of 2.03. The stock has fluctuated within a day range of 2.03 to 2.11, while its 52-week range spans from 1.67 to 9.95.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.